

PUBLICATIONS:

JOURNALS

All articles published in peer reviewed journals, listed in the Index Medicus.

1. S Ganeshalingam, G Rajeswaran, **Jones RL**, Thway K, Thomas M, Moskovic E. The cross sectional imaging appearances of leiomyosarcomas affecting the Inferior Vena Cava. Accepted *Clinical Radiology* July 2010.
2. Ratnayake G, Judson IR, Scurr M, Thway K, Fisher C, **Jones RL**. Fungal spinal cord compression in metastatic synovial sarcoma. Accepted *Acta Oncologica* June 2010.
3. Constantinidou A, **Jones RL**, Scurr M, Al-Muderis O, Judson I. The role of chemotherapy in aggressive fibromatosis. Accepted *Acta Oncologica* June 2010.
4. Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, **Jones RL**, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS. *PPM1D* gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic *in situ* hybridisation study. *Modern Pathology* published June 2010.
5. Almond M, **Jones RL**, Thway K, Fisher C, Moskovic E, Judson IR. Atypical metastatic spread in Stewart-Treves Syndrome. *Acta Oncologica* published June 2010.
6. Minchom A, **Jones RL**, Fisher C, Al-Muderis O, Ashley S, Scurr M, Judson IR. Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma. *Sarcoma* published May 2010.
7. **Jones RL**, Constantinidou A, Thway K, Ashley S, Scurr M, Al-Muderis O, Fisher C, Antonescu CR, D'Adamo DR, Keohan ML, Maki RG, Judson IR. Chemotherapy in clear cell sarcoma. Accepted *Medical Oncology* March 2010.
8. Constantinidou A, **Jones RL**, Reis-Filho JS. Beyond triple negative breast cancer – the need to define new subtypes. Accepted *Expert Review of Anticancer Therapy* March 2010.
9. Dowsett M, Dunbier A, Anderson H, Salter J, Detre S, **Jones R**, Skene A, Dixon M, Smith I. Biomarkers and predictive factors of response to neoadjuvant treatment. *Breast Cancer Research* **11** Supplement 1; S11: 2009
10. Olmos D, Tan DSW, **Jones RL**, Judson IR. Biological rationale and current clinical experience with anti-Insulin-like Growth Factor-1 receptor (IGF1-R) antibodies in treating sarcoma: twenty years from the bench to the bedside. *Cancer Journal* **16** (3); 183-194: 2010.
11. **Jones RL**, McCall J, Adam A, O'Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. *European Journal of Surgical Oncology* **36**(5); 477-482: 2010.
12. Constantinidou A, **Jones RL**, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well tolerated treatment for refractory aggressive fibromatosis. *European Journal of Cancer* **45**(17); 2930-2934: 2009.
13. Stummann TC, Beilmann M, Duker G, Dumotier B, Fredriksson JM, **Jones RL**, Hasiwa M, Kang J, Mandenius C-F, Meyer T, Minotti G, Jean-Pierre Valentin Y J-P, Zünkler BJ, Bremer S. Report and Recommendations of the Workshop of the

- European Centre for the Validation of Alternative Methods for Drug-induced Cardiotoxicity. *Cardiovascular Toxicology* **9(3)**; 107-125 2009.
14. **Jones RL**, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. *Breast Cancer Research and Treatment* **119(2)**; 315-323: 2010.
 15. Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, **Jones RL**, Blake P, Gabra H, Hall G, Gore ME, Kaye SB. A feasibility study of sequential doublet chemotherapy, comprising carboplatin/doxorubicin and carboplatin/paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. *Annals of Oncology* **20(11)**; 1787-1793: 2009.
 16. Lambros MBK, Tan DSP, **Jones RL**, Vatcheva R, Savage K, Tamber N, Fenwick K, Mackay A, Ashworth A, Reis-Filho JS. Genomic profile of a secretory breast cancer with an *ETV6-NTRK3* duplication. *Journal of Clinical Pathology* **62(7)**; 604-612: 2009.
 17. **Jones RL**, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, Johnston S, Smith IE. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. *British Journal of Cancer* **100(2)**; 305-310: 2009.
 18. **Jones RL**. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. *Expert Review of Cardiovascular Therapy* **6(10)**; 1311-1317: 2008.
 19. Sirohi B, Powles RL, Singhal S, Smith K, **Jones RL**, Saso R, Kulkarni S, Treleaven J, Swansbury GJ, Potter M, Morgan G, Mehta J. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia. *Leukaemia and Lymphoma* **49(12)**; 2284-2290: 2008.
 20. **Jones RL**, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. *Breast Cancer Research and Treatment* **11(6)**; 53-68: 2008.
 21. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, **Jones RL**, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G, Goebel G, Ensinger C, Jacobs I, Widschwendter M. Methylated *NEUROD1* promoter is a marker for chemosensitivity in breast cancer. *Clinical Cancer Research* **14(11)**; 3494-3502: 2008.
 22. Savage K, Leung S, Todd SK, Brown LA, **Jones RL**, Robertson D, James M, Parry S, Rodrigues Pinilla SM, Huntsman D, Reis-Filho JS. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. *Breast Cancer Research and Treatment* **110(2)**; 245-256: 2008.
 23. Tan DSP, Marchio C, **Jones RL**, Savage K, Smith IE, Dowsett M, Ashworth A, Reis-Filho JS. Triple Negative Breast Cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. *Breast Cancer Research and Treatment* **111(1)**; 27-44: 2008.

24. Lordan JT, **Jones RL**, Karanjia N, De Sanctis S, Middleton G, Menezes N. A rare case of a retroperitoneal enterogenous cyst with in-situ adenocarcinoma. *World Journal of Surgical Oncology* **5(1)**; 113: 2007.
25. Grosso F, **Jones RL**, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. *Lancet Oncology* **8(7)**; 595-602: 2007.
26. Lordan JT, **Jones RL**, Karanjia ND, Butler-Manuel S. Debulking hepatectomy for an unusual case of grade 1 stage 1 granulosa cell tumour of the ovary with late metastases. *Oncology* **72(1-2)**; 143-144: 2007.
27. Arriola E, Rodriguez-Pinilla SM, Lambros MBK, **Jones RL**, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. *Breast Cancer Research and Treatment* **106(2)**; 181-189: 2007.
28. Savage K, Lambros MBK, Robertson D, **Jones RL**, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CDM, Schmitt FC, Ashworth A, Reis-Filho JS. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphological, ultrastructural, immunohistochemical and *in situ* hybridisation analysis. *Clinical Cancer Research* 2007; **13(1)**: 90-101.
29. Rodriguez-Pinilla SM, **Jones RL**, Lambros MBK, Arriola E, Savage K, James M, Pinder SE, Reis-Filho JS. *MYC* amplification in breast cancer: a chromogenic *in situ* hybridisation study. *Journal of Clinical Pathology* **60(9)**; 1017-1023: 2007
30. **Jones RL**, Swanton C, Ewer MS. Anthracycline cardiotoxicity. *Expert Opinion Drug Safety* 2006; **5(6)**: 791-809.
31. **Jones RL**, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. *Expert Review Anticancer Therapy* 2006; **6(9)**: 1249-1269.
32. **Jones RL**, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. *Lancet Oncology* 2006; **7(10)**: 869-874.
33. **Jones RL**, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. *British Journal Cancer* 2006; **94(3)**: 358-62.
34. Reis-Filho JS, Savage K, Lambros M, James M, Steele D, **Jones RL**, Dowsett M. Cyclin D1 protein overexpression and *CCND1* amplification in breast carcinomas: an immunohistochemical and chromogenic *in situ* hybridisation analysis. *Modern Pathology* 2006; **19(7)**: 999-1009.
35. Reis-Filho JS, Steele D, Di Palma S, **Jones RL**, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A. Distribution and significance of nerve growth factor receptor (NGFR/p75^{NTR}) in normal, benign and malignant breast tissue. *Modern Pathology* 2006; **19**: 307-319.
36. **Jones RL**, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. *European Journal of Cancer* 2005; **41(18)**: 2853-2860.
37. **Jones RL**, Miles DW. Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity. *Lancet Oncology* 2005; **6**: 67.

38. **Jones RL**, Judson IR. The development and application of imatinib. *Expert Opinion on Drug Safety* 2005; **4**: 183-191.
39. **Jones RL**, Berry GJ, Rubens RD, Miles DW. Clinical and pathological absence of cardiotoxicity following liposomal doxorubicin. *Lancet Oncology* 2004; **5**: 575-577.
40. **Jones RL**, Smith IE. The efficacy and safety of Trastuzumab. *Expert Opinion on Drug Safety* 2004; **3(4)**: 317-327.
41. **Jones RL**, Cunningham D, Cook G, Ell PJ. Tumour vaccine associated lymphadenopathy and false positive PET scan changes. *British Journal of Radiology* 2004; **77**: 74-75.
42. **Jones RL**, Cunningham D. Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5FU-based chemotherapy. *Clinical Colorectal Cancer* 2003; **2(4)**: 235-238.
43. Chau I, **Jones R**, Cunningham D, Wotherspoon A, Maisey N, Norman A, Jaine P, Bishop L, Horwich A, Catovsky D. The outcome of follicular lymphoma grade 3a and 3b – is anthracycline necessary as front line therapy. *British Journal of Cancer* 2003; **89**: 36-42.
44. Hopkins KD, Lehmann ED, **Jones RL**, Holly IMP, Cwyfan-Hughes SC, Turay RC, Gosling RG. Ethnicity affects IGF BP III and IGF II in normal young adult subjects. *Clinical Endocrinology* 1996; **45**: 327-33
45. Hopkins KD, Lehmann ED, **Jones RL**, Turay RC, Gosling RG. A family history of non-insulin-dependent diabetes mellitus is associated with decreased aortic distensibility in normal healthy young adult subjects. *Diabetes Care* 1996; **19**: 501-503.
46. Lehmann ED, Hopkins KD, **Jones RL**, Rudd AG, Gosling RG. Aortic distensibility in patients with cerebrovascular disease. *Clinical Science* 1995; **89**: 247-253.
47. Lehmann ED, Hopkins KD, Marsden RM, Brown I, **Jones RL**, Turay RC, Taylor MG, Gosling RG. Aortic compliance measured by a non-invasive personal computer based Mk. II system and its repeatability. *Medical Engineering and Physics* 1994; **16**: 213-221.

BOOK CHAPTERS AND NON-PEER REVIEWED ARTICLES:

1. **Jones RL**. The cardioprotective value of dexrazoxane in adult and paediatric patients. In: Hellmann and Rhomberg, eds. *Razoxane and dexrazoxane – two multifunctional agents. Experimental and clinical results*. Springer, 2010.
2. **Jones RL**, Judson IR. Gastro-intestinal stromal tumours: what exactly constitutes evidence based management. In: Miles A, ed. *Upper Gastrointestinal Malignancies*. UK Key Advances in Clinical Practice Series, due to be published 2010 (2nd Edition).
3. **Jones RL**, Karavasilis V, Kaye SB. Paclitaxel in the management of ovarian cancer. *Expert Review of Obstetrics and Gynecology* 2008; **3(3)**: 287-299.
4. **Jones RL**, Smith IE. Pre-operative endocrine therapy: focus on the clinical and biological results of the IMPACT trial. *Breast Cancer Online* 2006; **9**: 1-3.

5. **Jones RL**, Smith IE. Trastuzumab and other novel therapies in breast cancer. In: Swanton C, Johnston S, eds. *Metastatic Breast Cancer Handbook*. Taylor Francis Books, 2005.
6. **Jones RL**. Targeted therapy in breast cancer. *Hospital Pharmacy Europe* 2005; 19: 53-57.
7. **Jones RL**, Smith IE. Oncology. In: N Ali, ed. *Alarm Bells in Medicine*. BMJ Books, 2005.
8. **Jones RL**, Andrews PRL. Nausea and vomiting associated with chemotherapy: physiological mechanisms and pharmacological perspectives. In: Hoy A, Finlay I, Miles A, eds. *The Effective Prevention and Control of Symptoms in Cancer*. Key Advances in Clinical Practice Series, 2003.
9. **Jones RL**, Cunningham D. Chemotherapy protocols for lower gastro-intestinal cancer. In: Dearnaley DP, Judson I, Root T, eds. *The Royal Marsden Handbook of Adult Cancer Chemotherapy Schedules*. TMG Healthcare, 2002.